NCT04783402

Brief Summary

The present randomized controlled trial has the main objective to study the effects of a videoconferenced occupational therapy program in preventing cancer and chemotherapy-related cognitive impairment and other health outcomes, as well as in improving quality of live and occupational performance of women undergoing chemotherapy for breast cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
98

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 31, 2020

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 21, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 5, 2021

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

December 11, 2023

Status Verified

December 1, 2023

Enrollment Period

4.2 years

First QC Date

February 21, 2021

Last Update Submit

December 4, 2023

Conditions

Keywords

ChemotherapyOccupational TherapyQuality of LifeCognitive ImpairmentBreast Neoplasms

Outcome Measures

Primary Outcomes (1)

  • Subjective cognitive Function:

    The primary outcome will be assessed with the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) will be used to assess the subjective cognitive functioning.

    Participants will be followed over 6 months

Secondary Outcomes (8)

  • Objective Cognitive Function: Attention

    Participants will be followed over 6 months

  • Objective Cognitive Function: Verbal Memory

    Participants will be followed over 6 months

  • Objective Cognitive Function: Working Memory and Processing Speed

    Participants will be followed over 6 months

  • Psychological status

    Participants will be followed over 6 months

  • Cancer-Related Fatigue

    Participants will be followed over 6 months.

  • +3 more secondary outcomes

Study Arms (2)

e-OTCAT

EXPERIMENTAL

The experimental group will receive the e-OTCAT program that consists of a 12-week videoconference-based occupational therapy intervention at the same time women with breast cancer receive chemotherapy.

Other: e-OTCAT program

Control Group

OTHER

At the beginning of chemotherapy, the participants allocated to the control group will only receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care for these patients.

Other: Educational handbook and standard care

Interventions

The e-OTCAT program consists of a combination of cognitive training in terms of attention, memory and processing speed; and adaptive training based on metacognition and cognitive-behavioral strategies (psycho-education, relaxation techniques training, stress management, energy conservation techniques, time management, etc.). This program also includes homework exercises consisting of a handbook of paper-and-pencil exercises, a cognitive training mobile app, and the practice of strategies seen in adaptive training sessions.

e-OTCAT

At the beginning of chemotherapy, the participants will receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care.

Control Group

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Female with breast cancer who are going to start chemotherapy
  • Stage I-III breast cancer
  • No evidence of disease at time of screening
  • Must be able to speak, read and write Spanish well to complete written and verbal assessment, neurocognitive tests and study tasks
  • Must have basic phone skills

You may not qualify if:

  • History of neurological disorder with cognitive symptoms (i.e., Parkinson's disease, Alzheimer disease, seizure disorder, multiple sclerosis, etc.)
  • History of psychiatric disorder such as mental retardation, bipolar disorder, schizophrenia, etc.
  • History of traumatic brain injury with ≥ 30' of consciousness or cognitive sequelae as per self-report or as documented in the medical record
  • Prior history of cancer or secondary diagnosis of cancer
  • Prior history of chemotherapy
  • A hearing or visual deficit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Granada

Granada, 18016, Spain

Location

Related Publications (1)

  • Gonzalez-Santos A, Lopez-Garzon M, Sanchez-Salado C, Postigo-Martin P, Lozano-Lozano M, Galiano-Castillo N, Fernandez-Lao C, Castro-Martin E, Gallart-Aragon T, Legeren-Alvarez M, Gil-Gutierrez R, Martin-Martin L. A Telehealth-Based Cognitive-Adaptive Training (e-OTCAT) to Prevent Cancer and Chemotherapy-Related Cognitive Impairment in Women with Breast Cancer: Protocol for a Randomized Controlled Trial. Int J Environ Res Public Health. 2022 Jun 10;19(12):7147. doi: 10.3390/ijerph19127147.

MeSH Terms

Conditions

Breast NeoplasmsCognitive Dysfunction

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesCognition DisordersNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Single
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer, PhD researcher and investigator

Study Record Dates

First Submitted

February 21, 2021

First Posted

March 5, 2021

Study Start

October 31, 2020

Primary Completion

December 30, 2024

Study Completion

December 30, 2024

Last Updated

December 11, 2023

Record last verified: 2023-12

Locations